Pfizer's drug combination therapy shows positive results in late-stage trials

Pfizer and Astellas Pharma announced that their drug Padcev in combination with Merck's Keytruda has achieved positive results in late-stage trials for the treatment of bladder cancer. The trials showed significant improvements in both event-free survival and overall survival rates, paving the way for subsequent regulatory submissions. This progress will strengthen Pfizer's product pipeline in the field of oncology